

Summary of Financial Report for the 3rd Quarter of FY ending December 2010

November 12, 2010

Company Name: Carna Biosciences, Inc.
 Stock exchange listing: Osaka Securities Exchange
 Stock Code: 4572
 URL: <http://www.carnabio.com>
 Representative: Kohichiro Yoshino, President
 Contact: Norio Aikawa, Director
 TEL +81-78-302-7039

(Rounding down to the nearest million yen)

1. Consolidated results for the 3rd Quarter of FY2010 (January 1, 2010 to September 30, 2010)

(1) Business Results (Consolidated) (% indicates increases or decreases from the previous year)

	Total Revenue		Operating income		Ordinary income		Net income	
	million yen	%	million yen	%	million yen	%	million yen	%
3 rd quarter of FY2010	432	-13.7	-300	-	-269	-	-296	-
3 rd quarter of FY2009	501	-	-229	-	-226	-	-189	-

	Net income per share	Net income per share (diluted)
	yen	yen
3 rd quarter of FY2010	-5,043.45	-
3 rd quarter of FY2009	-3,554.76	-

Note: Net income per share of 3rd quarter of FY2009 and 2010(Diluted): No statement - We had net loss per share even though we had diluted shares.

(2) Financial Condition (Consolidated)

	Total assets	Net assets	Equity ratio	Net assets per share
	million yen	million yen	%	Yen
3 rd quarter of FY2010	1,743	1,481	85.0	25,234.35
FY2009 as reference	2,043	1,801	88.1	30,680.71

2. Cash Dividends

(criterion)	Dividends per share				
	End of 1 st quarter period	End of 2 nd quarter period	End of 3 rd quarter period	End of FY	FY
	yen	yen	yen	yen	yen
FY2009	-	0.00	-	0.00	0.00
FY2010	-	0.00	-		
FY2010(forecast)				0.00	0.00

3. Consolidated forecast for FY2010 (January 1, 2010 to December 31, 2010)

(% indicates increases or decreases from the previous year)

	Total revenue		Operating income		Ordinary income		Net income		Net income per share
	million yen	%	million yen	%	million yen	%	million yen	%	Yen
FY2010	740	7.7	-344	-	-315	-	-344	-	-5,868.78

*Disclaimer regarding appropriate use of forecasts and related points of note

1. The above-mentioned forecasts are based on the information available on the date of release of these materials and on various assumptions made on the date of release of these material including uncertain factors and may affect future earnings. Actual operating results may differ significantly from those forecasts as a consequence of various factors.

2. The forecasted net income per share above is calculated based on 58,710 issued shares.